The inhalation company Inhalation Sciences reports increased revenue in the second quarter compared with the same period the year before. The operating loss narrowed.Revenue rose to SEK 2.7 million (0.8).Operating result was -SEK 1.8 million (-2.5). Net result after tax was -SEK 1.7 million (-2.5), and per share -SEK 0.03 (-0.11). Order intake amounted to SEK 1.7 million (0.9), an increase of 88.9 percent year-over-year. Cash and cash equivalents amounted to SEK 1.7 million (9.8)."Despite an uncertain market with geopolitical challenges, American customers who have become more orless forced to choose domestic technology and customers whose research budgets havebeen withdrawn or postponed, we at ISAB have continued to improve our revenue and after the first 6months of the year, have been able to see a doubling compared with 2025 revenue. However, we are notsatisfied and are continuing purposefully with our commercial activities in order to deliver at leastas well in the second half of the year. This, combined with an improved operating result and ourconscious focus on cost control, should lead to a much better full year than the previous year, withthe ambition of approaching profitability by the end of the year," comments CEO Manoush Masarrat.Inhalation Sciences, SEK millionQ2-2026Q2-2025ChangeOrder intake1.70.988.9%Net revenue2.70.8237.5%Operating result-1.8-2.5Net result-1.7-2.5Earnings per share, SEK-0.03-0.11Cash and cash equivalents1.79.8-82.7%